



## ***Disclosure of total number of voting rights and number of shares in the capital at October 30, 2009***

Paris, November 10, 2009 – Pursuant to article L.233-8 II of the *Code de commerce* (the French Commercial Code) and article 223-16 of the *Règlement général de l’Autorité des Marchés Financiers* (Regulation of the French stock market authority):

Date	Total number of outstanding shares	Total number of voting rights
October 30, 2009	12, 896,834	Theoretical number of voting rights: 12, 896,834 (including treasury shares)  Number of real voting rights: 12, 847,537 (without treasury shares)

### **About BioAlliance Pharma**

BioAlliance Pharma SA is a company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues.

### ***BioAlliance Pharma SA***

Dominique Costantini, President and CEO  
 Tel.: +33 1 45 58 76 01  
[dominique.costantini@bioalliancepharma.com](mailto:dominique.costantini@bioalliancepharma.com)

Nicolas Fellmann, CFO  
 Tel.: +33 1 45 58 71 00  
[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

### ***ALIZE RP***

Caroline Carmagnol  
 Tel.: +33 6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)